Top New Picks of Healthcare Fund Blue Jay Capital: Endo International plc (ENDP), Alkermes Plc (ALKS), Akorn Inc. (AKRX)

Akorn Inc. (NASDAQ:AKRX) occupies the third spot in the ranking of the top new holdings of Blue Jay Capital, which reported holding 300,000 shares of the company worth $14.25 million. Akorn Inc. (NASDAQ:AKRX) is a $4.8-billion market cap specialty pharmaceutical company. Last year, the company received 14 unique product approvals, and launched five of these products during the year. The company expects to launch the remaining nine products in 2015. For the fiscal fourth quarter of 2014, the company reported revenue of $227.8 million, representing a 168% increase year-over-year. Among the investors we track, Mitchell Blutt’s Consonance Capital Management held a position of 1.68 million shares in Akorn at the end of 2014.

In Impax Laboratories Inc (NASDAQ:IPXL), Blue Jay Capital revealed holding 285,000 shares with a reported value of $13.36 million. Impax Laboratories Inc (NASDAQ:IPXL) is a technology-based specialty pharmaceutical company, with a market cap of $3.2 billion. In the early part of 2015, the company announced that it received approval for RYTARY, an extended-release oral capsule formulation of carbidopa-levodopa, for the treatment of Parkinson’s disease, post-encephalitic parkinsonism, and parkinsonism. Impax Laboratories Inc (NASDAQ:IPXL) reported a $24.4 million increase in its first-quarter 2015 total revenues to $143.1 million versus $118.7 million in the prior year’s period. The increase is attributed to higher sales. However, it posted a net loss of -$6.3 million, or -$0.09 per share for the quarter, versus a loss of -$6.4 million, or -$0.09 per share, in the same quarter of 2014. Since May 2014, Impax Laboratories Inc’s (NASDAQ:IPXL) stock has increased by nearly 78%. Among the largest shareholders of the company is Samuel Isaly’s Orbimed Advisors, which held 6.68 million shares at the end of 2014.

Disclosure: None